IDO1 and breast cancer: The most recent clinical trial publishing the effect of an IDO1/TDO2 inhibitor, Indoximod (D-1MT/NLG-8189), did not show a clinical benefit in metastatic BC patients when combined with taxane chemotherapy [47].